Kiora Pharmaceuticals Inc.

KPRX Nasdaq SEC CIK 1372514
Follow Kiora Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $1M
Net income −$1.7M −6626.6% vs same quarter last year
EPS, diluted −$0.28 −2900% vs same quarter last year
Operating cash flow −$557.5K +56.2% vs same quarter last year
Revenue by quarter
$0
$0
$0
$0
$0
$1M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income13 fiscal years
  • Revenue
  • Net income
−$20M−$10M$0$10M$20MFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$0−$10.8K
FY24$16M$3.6K
FY23$0−$12.5K
FY22-−$13.6M
FY21$0−$13.8M
FY20$12.1K−$6.9M
FY19$2.7M−$7.1M
FY18$1.7M−$10.8M
FY17$407.5K−$13.2M
FY16$669.3K−$13.3M
FY15$0−$8.4M
FY14-−$1.6M
FY13--
MarginsShare of revenue
  • Operating margin
  • Net margin
−60000%−40000%−20000%0%20000%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25--
FY2428.2%0%
FY23--
FY22--
FY21--
FY20−56960.5%−56901.7%
FY19-−264.2%
FY18−656.3%−654.2%
FY17-−3243.5%
FY16-−1993.8%
FY15--
FY14--
FY13--
Free cash flowOperating cash flow minus capital expenditure
−$15M−$10M−$5M$0$5M$10MFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$10.1M
FY24$8.6M
FY23−$9.6M
FY22−$10.4M
FY21−$10.7M
FY20−$7.3M
FY19−$8.2M
FY18−$10.9M
FY17−$6.5M
FY16−$8.4M
FY15-
FY14-
FY13-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Kiora Pharmaceuticals
  • Healthcare median
−60000%−40000%−20000%0%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearKiora PharmaceuticalsHealthcare median
FY25-−30.6%
FY240%−47%
FY23-−58%
FY22-−80.4%
FY21-−71.8%
FY20−56901.7%−62.2%
FY19−264.2%−46.2%
FY18−654.2%−49.6%
FY17−3243.5%−45.9%
FY16−1993.8%−36%
FY15-−37.8%
FY14-−35.5%
FY13-−37.1%